1.Sales and profit
See section β- Kiora Pharmaceuticals Inc had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
- Kiora Pharmaceuticals Inc lost $10.8M in fiscal 2025.
Kiora Pharmaceuticals Inc
KPRX Nasdaq Pharmaceutical Preparations Financials FY2016βFY2025
Kiora Pharmaceuticals Inc had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
Download report
3-page PDF: the company, its results and charts with peers.
Last close Β· Oct 23, 2026
$2.29
1.3%KIRAβs summary AI analyst
Hi! I read Kiora Pharmaceuticals Incβs latest annual report (fiscal 2025). Here is what stands out:
4 to watch
2.Cash and shareholders
See section β- Free cash flow was β$10.1M in fiscal 2025, β of revenue.
- No open-market insider trades in the last 12 months.
3.Financial health
See section β- Kiora Pharmaceuticals Inc passes 3 of 7 financial health tests (Piotroski F-score).
Kiora Pharmaceuticals Inc in 30 seconds
Good So-so Weak
Weak
Are sales growing?
β100.0%
No. Sales fell 100.0% last year.
Weak
Does it make a profit?
β$10.8M
No. It lost money last year.
Weak
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
For information
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Key numbers, fiscal 2025
Market cap
Last close times the latest diluted share count, so it is approximate.
$14.1M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
β
On β$2.50 EPS (TTM)
Charts by
Sales and profit
Is it selling more, and how much does it keep?
Results dates
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Kiora Pharmaceuticals Inc did it, and the next one. Share prices often move a lot on those days.
Next results
November 6, 2026
Friday Β· in 11 days
- Time
- Time not announced
- Covers
- Period ended Sep 30, 2026
- Source
- Earnings calendar
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 7, 2026 | Q2 '26 | Before the market opens | 8-K β |
| May 8, 2026 | Q1 '26 | Before the market opens | 8-K β |
| Mar 25, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 7, 2025 | Q3 '25 | Before the market opens | 8-K β |
| Aug 8, 2025 | Q2 '25 | Before the market opens | 8-K β |
| May 9, 2025 | Q1 '25 | Before the market opens | 8-K β |
| Mar 25, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Nov 8, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
Revenue and margins
KIRA Β· Kiora Pharmaceuticals Inc had $0.0M of revenue in fiscal 2025, down 100.0% on the year before.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
FY16
Revenue $0.7M
FY17
Revenue $0.4M
FY18
Revenue $1.7M
FY19
Revenue $2.7M
FY20
Revenue $0.0M
FY21
Revenue $0.0M
FY22
Revenue β
FY23
Revenue $0.0M
FY24
Revenue $16.0M
FY25
Revenue $0.0M
Revenue
Q3 '23
Revenue $0.0M
Q4 '23
Revenue $0.0M
Q1 '24
Revenue $16.0M
Q2 '24
Revenue $0.0M
Q3 '24
Revenue $0.0M
Q4 '24
Revenue $0.0M
Q1 '25
Revenue $0.0M
Q2 '25
Revenue $0.0M
Q3 '25
Revenue $0.0M
Q4 '25
Revenue $0.0M
Q1 '26
Revenue β
Q2 '26
Revenue β
Margins, % of revenue
FY16
Gross β
Operating β
Net β1,993.6%
FCF β1,257.0%
FY17
Gross β
Operating β
Net β3,243.7%
FCF β1,596.4%
FY18
Gross β
Operating β656.3%
Net β654.2%
FCF β657.5%
FY19
Gross β
Operating β
Net β264.2%
FCF β303.6%
FY20
Gross β
Operating β56,767.8%
Net β56,709.1%
FCF β60,638.8%
FY21
Gross β
Operating β
Net β
FCF β
FY22
Gross β
Operating β
Net β
FCF β
FY23
Gross β
Operating β
Net β
FCF β
FY24
Gross β
Operating 28.2%
Net 22.4%
FCF 53.4%
FY25
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Margins, % of revenue
Q3 '23
Gross β
Operating β
Net β
FCF β
Q4 '23
Gross β
Operating β
Net β
FCF β
Q1 '24
Gross β
Operating 82.6%
Net 84.1%
FCF β
Q2 '24
Gross β
Operating β12,724.5%
Net β11,108.0%
FCF β
Q3 '24
Gross β
Operating β
Net β
FCF β
Q4 '24
Gross β
Operating β
Net β
FCF β
Q1 '25
Gross β
Operating β
Net β
FCF β
Q2 '25
Gross β
Operating β
Net β
FCF β
Q3 '25
Gross β
Operating β
Net β
FCF β
Q4 '25
Gross β
Operating β
Net β
FCF β
Q1 '26
Gross β
Operating β
Net β
FCF β
Q2 '26
Gross β
Operating β
Net β
FCF β
Gross
Operating
Net
FCF
Net income and earnings per share
KIRA Β· Kiora Pharmaceuticals Inc lost $10.8M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
FY16
Net income β$13.3M
FY17
Net income β$13.2M
FY18
Net income β$10.8M
FY19
Net income β$7.1M
FY20
Net income β$6.9M
FY21
Net income β$13.8M
FY22
Net income β$13.6M
FY23
Net income β$12.5M
FY24
Net income $3.6M
FY25
Net income β$10.8M
Net income
Q3 '23
Net income β$5.8M
Q4 '23
Net income β$2.3M
Q1 '24
Net income $13.5M
Q2 '24
Net income β$2.2M
Q3 '24
Net income β$3.4M
Q4 '24
Net income β$4.2M
Q1 '25
Net income β$2.2M
Q2 '25
Net income β$2.2M
Q3 '25
Net income $0.0M
Q4 '25
Net income β$6.5M
Q1 '26
Net income β$2.4M
Q2 '26
Net income β$2.1M
Diluted EPS
FY16
Diluted EPS β$1.51
FY17
Diluted EPS β$0.93
FY18
Diluted EPS β$4.57
FY19
Diluted EPS β$2.23
FY20
Diluted EPS β$1.49
FY21
Diluted EPS β$57.12
FY22
Diluted EPS β$18.55
FY23
Diluted EPS β$24.25
FY24
Diluted EPS $0.87
FY25
Diluted EPS β$2.64
Diluted EPS
Q3 '23
Diluted EPS β$7.30
Q4 '23
Diluted EPS β$8.80
Q1 '24
Diluted EPS $3.46
Q2 '24
Diluted EPS β$0.53
Q3 '24
Diluted EPS β$0.81
Q4 '24
Diluted EPS β$1.25
Q1 '25
Diluted EPS β$0.52
Q2 '25
Diluted EPS β$0.54
Q3 '25
Diluted EPS $0.01
Q4 '25
Diluted EPS β$1.59
Q1 '26
Diluted EPS β$0.58
Q2 '26
Diluted EPS β$0.34
Cash and shareholders
How much cash comes in, and where does it go?
Cash flow
KIRA Β· Free cash flow was β$10.1M in fiscal 2025, β of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
FY16
Free cash flow β$8.4M
FY17
Free cash flow β$6.5M
FY18
Free cash flow β$10.9M
FY19
Free cash flow β$8.2M
FY20
Free cash flow β$7.3M
FY21
Free cash flow β$10.7M
FY22
Free cash flow β$10.4M
FY23
Free cash flow β$9.6M
FY24
Free cash flow $8.6M
FY25
Free cash flow β$10.1M
Free cash flow
Q3 '23
Free cash flow β$2.5M
Q4 '23
Free cash flow β$2.6M
Q1 '24
Free cash flow β
Q2 '24
Free cash flow β
Q3 '24
Free cash flow $0.9M
Q4 '24
Free cash flow β$2.2M
Q1 '25
Free cash flow β$2.7M
Q2 '25
Free cash flow β$3.8M
Q3 '25
Free cash flow β$1.3M
Q4 '25
Free cash flow β$2.3M
Q1 '26
Free cash flow β$3.2M
Q2 '26
Free cash flow β$1.9M
Cash from operations vs capital spending
FY16
Cash from operations β$8.4M
Capital spending $0.0M
FY17
Cash from operations β$6.5M
Capital spending $0.0M
FY18
Cash from operations β$10.8M
Capital spending $0.0M
FY19
Cash from operations β$8.2M
Capital spending $0.0M
FY20
Cash from operations β$7.3M
Capital spending $0.0M
FY21
Cash from operations β$10.7M
Capital spending $0.1M
FY22
Cash from operations β$10.4M
Capital spending $0.0M
FY23
Cash from operations β$9.6M
Capital spending $0.0M
FY24
Cash from operations $8.6M
Capital spending $0.0M
FY25
Cash from operations β$10.0M
Capital spending $0.1M
Cash from operations
Capital spending
Cash from operations vs capital spending
Q3 '23
Cash from operations β$2.5M
Capital spending $0.0M
Q4 '23
Cash from operations β$2.6M
Capital spending $0.0M
Q1 '24
Cash from operations $13.6M
Capital spending β
Q2 '24
Cash from operations β$3.7M
Capital spending β
Q3 '24
Cash from operations $0.9M
Capital spending $0.0M
Q4 '24
Cash from operations β$2.3M
Capital spending β$0.0M
Q1 '25
Cash from operations β$2.7M
Capital spending $0.0M
Q2 '25
Cash from operations β$3.8M
Capital spending $0.0M
Q3 '25
Cash from operations β$1.3M
Capital spending $0.0M
Q4 '25
Cash from operations β$2.2M
Capital spending $0.1M
Q1 '26
Cash from operations β$3.2M
Capital spending $0.0M
Q2 '26
Cash from operations β$1.9M
Capital spending $0.0M
Cash from operations
Capital spending
Dividends, buybacks and share count
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
FY16
Dividends β
Buybacks β
FY17
Dividends β
Buybacks β
FY18
Dividends β
Buybacks β
FY19
Dividends β
Buybacks β
FY20
Dividends β
Buybacks β
FY21
Dividends β
Buybacks β
FY22
Dividends β
Buybacks β
FY23
Dividends β
Buybacks β
FY24
Dividends β
Buybacks β
FY25
Dividends β
Buybacks β
Dividends
Buybacks
Diluted shares outstanding (annual)
FY16
Diluted shares 0.01B
FY17
Diluted shares 0.01B
FY18
Diluted shares 0.00B
FY19
Diluted shares 0.00B
FY20
Diluted shares 0.00B
FY21
Diluted shares 0.00B
FY22
Diluted shares 0.00B
FY23
Diluted shares 0.00B
FY24
Diluted shares 0.00B
FY25
Diluted shares 0.00B
Insider trades
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Financial health
Can it carry its debts, and how well does it use its money?
Balance sheet
Cash, debt and the ratios that show how comfortably Kiora Pharmaceuticals Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
FY16
Cash $3.6M
Debt β
FY17
Cash $7.8M
Debt β
FY18
Cash $8.0M
Debt β
FY19
Cash $3.8M
Debt $0.0M
FY20
Cash $1.2M
Debt $0.3M
FY21
Cash $7.9M
Debt β
FY22
Cash $6.0M
Debt β
FY23
Cash $2.5M
Debt β
FY24
Cash $26.8M
Debt β
FY25
Cash $17.1M
Debt β
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $7.9M | $6.0M | $2.5M | $26.8M | $17.1M |
| Interest coverage | β2,063.2x | β1,431.3x | β1,134.0x | 210.8x | β641.6x |
| Current ratio | 5.6x | 2.3x | 2.9x | 4.9x | 6.0x |
| Quick ratio | 5.6x | 2.3x | 2.9x | 4.9x | 6.0x |
| Total assets | $20.1M | $18.7M | $13.7M | $36.5M | $24.3M |
| Total liabilities | $5.6M | $7.3M | $7.6M | $10.7M | $8.1M |
| Shareholders' equity | $14.6M | $11.4M | $6.1M | $25.8M | $16.1M |
| Net debt (β = net cash) | β | β | β | β | β |
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
FY16
Return on capital β
Return on equity β
Return on assets β137.1%
FY17
Return on capital β
Return on equity β
Return on assets β110.0%
FY18
Return on capital β
Return on equity β308.5%
Return on assets β75.6%
FY19
Return on capital β
Return on equity β91.2%
Return on assets β58.2%
FY20
Return on capital β61.5%
Return on equity β83.9%
Return on assets β54.0%
FY21
Return on capital β
Return on equity β113.3%
Return on assets β77.7%
FY22
Return on capital β
Return on equity β104.5%
Return on assets β70.0%
FY23
Return on capital β
Return on equity β142.9%
Return on assets β77.3%
FY24
Return on capital β
Return on equity 22.6%
Return on assets 14.3%
FY25
Return on capital β
Return on equity β51.7%
Return on assets β35.7%
Return on capital
Return on equity
Return on assets
Piotroski F-score
KIRA Β· Kiora Pharmaceuticals Inc passes 3 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 3 / 7 | 4 / 7 | 3 / 7 | 1 / 8 | 3 / 7 | β / 6 | β / 6 | 6 / 7 | 3 / 7 |
| Accruals ratio | β50.7% | β56.2% | 0.2% | 8.7% | 3.6% | β17.5% | β16.3% | β18.3% | β19.8% | β2.9% |
| Altman Z'' | β | β | β22.49 | β | β24.11 | β19.17 | β24.70 | β38.78 | β5.20 | β17.30 |
All figures
Every number, year by year.
10 years of figures
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $0.7M | $0.4M | $1.7M | $2.7M | $0.0M | $0.0M | β | $0.0M | $16.0M | $0.0M |
| Research and development | $8.4M | $10.3M | $8.1M | $5.4M | $3.6M | $5.4M | $3.4M | $4.0M | $7.8M | $10.8M |
| Operating income | β | β | β$10.8M | β | β$6.9M | β$14.2M | β$12.3M | β$12.6M | $4.5M | β$12.8M |
| Interest expense | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Pretax income | β$13.3M | β$14.6M | β$10.7M | β$7.0M | β$6.8M | β$14.0M | β$13.7M | β$12.4M | $5.7M | β$12.1M |
| Income tax | $0.0M | β$1.3M | $0.1M | $0.1M | $0.0M | β$0.2M | β$0.1M | $0.1M | $2.1M | β$1.3M |
| Net income | β$13.3M | β$13.2M | β$10.8M | β$7.1M | β$6.9M | β$13.8M | β$13.6M | β$12.5M | $3.6M | β$10.8M |
| Net income to common | β$13.3M | β | β | β | β | β | β | β | β | β |
| Diluted EPS | β$1.51 | β$0.93 | β$4.57 | β$2.23 | β$1.49 | β$57.12 | β$18.55 | β$24.25 | $0.87 | β$2.64 |
| Diluted shares | 0.01B | 0.01B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$8.4M | β$6.5M | β$10.8M | β$8.2M | β$7.3M | β$10.7M | β$10.4M | β$9.6M | $8.6M | β$10.0M |
| Capital expenditure | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M | $0.1M |
| Free cash flow | β$8.4M | β$6.5M | β$10.9M | β$8.2M | β$7.3M | β$10.7M | β$10.4M | β$9.6M | $8.6M | β$10.1M |
| Depreciation and amortization | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M |
| Stock-based compensation | $0.5M | $0.9M | $0.9M | $0.9M | $0.7M | $0.8M | $0.5M | $0.8M | $0.7M | $0.9M |
| Acquisitions | β | β | β | β | $0.1M | $0.1M | $0.0M | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $3.6M | $7.8M | $8.0M | $3.8M | $1.2M | $7.9M | $6.0M | $2.5M | $26.8M | $17.1M |
| Total debt | β | β | β | $0.0M | $0.3M | β | β | β | β | β |
| Current assets | $4.2M | $8.5M | $8.5M | $4.3M | $1.7M | $9.0M | $7.7M | $4.7M | $29.7M | $21.7M |
| Current liabilities | $7.3M | $14.8M | $3.9M | $1.4M | $2.0M | $1.6M | $3.3M | $1.6M | $6.0M | $3.6M |
| Property and equipment, net | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | $0.0M | $0.0M | $0.1M |
| Goodwill | β | $1.5M | $1.5M | $1.5M | $3.6M | $0.0M | $0.0M | β | β | β |
| Intangible assets | β | $3.9M | $4.2M | $4.1M | $9.7M | $10.8M | $10.7M | $8.8M | $6.7M | $2.1M |
| Total assets | $9.7M | $14.3M | $14.3M | $10.1M | $15.3M | $20.1M | $18.7M | $13.7M | $36.5M | $24.3M |
| Total liabilities | $10.1M | $16.2M | $5.3M | $3.5M | $5.6M | $5.6M | $7.3M | $7.6M | $10.7M | $8.1M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$0.3M | β$1.9M | $8.9M | $6.6M | $9.7M | $14.6M | $11.4M | $6.1M | $25.8M | $16.1M |
| Margins | ||||||||||
| Operating margin | β | β | β656.3% | β | β56,767.8% | β | β | β | 28.2% | β |
| EBITDA margin | β | β | β653.9% | β | β56,491.7% | β | β | β | 28.3% | β |
| Net margin | β1,993.6% | β3,243.7% | β654.2% | β264.2% | β56,709.1% | β | β | β | 22.4% | β |
| FCF margin | β1,257.0% | β1,596.4% | β657.5% | β303.6% | β60,638.8% | β | β | β | 53.4% | β |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β61.5% | β | β | β | β | β |
| Return on capital employed | β | β | β104.1% | β | β51.6% | β76.9% | β79.9% | β104.2% | 14.8% | β62.2% |
| Return on equity | β | β | β308.5% | β91.2% | β83.9% | β113.3% | β104.5% | β142.9% | 22.6% | β51.7% |
| Return on assets | β137.1% | β110.0% | β75.6% | β58.2% | β54.0% | β77.7% | β70.0% | β77.3% | 14.3% | β35.7% |
| Return on tangible equity | β | β | β332.2% | β735.0% | β | β361.4% | β2,044.5% | β | 18.8% | β77.0% |
| Growth | ||||||||||
| Revenue growth | β | β39.1% | 305.5% | 62.5% | β99.5% | β100.0% | β | β | β | β100.0% |
| Net income growth | β | β | β | β | β | β | β | β | β | β401.4% |
| EPS growth | β | β | β | β | β | β | β | β | β | β403.4% |
| FCF growth | β | β | β | β | β | β | β | β | β | β217.8% |
| Share count change | β | 61.4% | β83.4% | 34.5% | 44.3% | β94.7% | 203.7% | β26.5% | 666.7% | β0.5% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | 0.0x | 0.0x | β | β | β | β | β |
| Interest coverage | β | β | β10,844.7x | β | β1,635.5x | β2,063.2x | β1,431.3x | β1,134.0x | 210.8x | β641.6x |
| Current ratio | 0.6x | 0.6x | 2.2x | 3.1x | 0.9x | 5.6x | 2.3x | 2.9x | 4.9x | 6.0x |
| Quick ratio | 0.6x | 0.6x | 2.2x | 3.1x | 0.9x | 5.6x | 2.3x | 2.9x | 4.9x | 6.0x |
| Capital allocation | ||||||||||
| Capex / revenue | 0.0% | 9.1% | 1.2% | 0.0% | 166.1% | β | β | β | 0.0% | β |
| Stock comp / revenue | 76.3% | 213.6% | 53.0% | 31.7% | 5,982.6% | β | β | β | 4.1% | β |
| Quality scores | ||||||||||
| Piotroski F-score | β | 3.0 | 4.0 | 3.0 | 1.0 | 3.0 | β | β | 6.0 | 3.0 |
| Altman Z'' | β | β | β22.5 | β | β24.1 | β19.2 | β24.7 | β38.8 | β5.2 | β17.3 |
| Accruals ratio | β50.7% | β56.2% | 0.2% | 8.7% | 3.6% | β17.5% | β16.3% | β18.3% | β19.8% | β2.9% |
Source: SEC EDGAR XBRL filings (CIK 0001372514). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.